Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
| Autor: | Cornelius F. Waller, Adolfo Fuentes-Alburo, Julia Möbius |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Receptor ErbB-2 Cost-Benefit Analysis Injections Subcutaneous Breast Neoplasms Review Article 03 medical and health sciences Route of administration Breast cancer 0302 clinical medicine Trastuzumab Internal medicine medicine Chemotherapy Humans 030212 general & internal medicine skin and connective tissue diseases Biosimilar Pharmaceuticals neoplasms Human Epidermal Growth Factor Receptor 2 Clinical Trials as Topic business.industry Biosimilar medicine.disease Patient preference Clinical Practice Treatment Outcome 030220 oncology & carcinogenesis Administration Intravenous Female business Healthcare providers medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab was originally approved as an intravenous (IV) formulation but has since been developed for subcutaneous (SC) administration for patients with HER2-positive breast cancer. Both formulations demonstrate generally comparable pharmacological and clinical profiles. Therefore, when deciding between treatment options, factors such as the route of administration, patient preference, value and cost must be considered. Studies comparing IV with SC trastuzumab indicate that each formulation offers unique advantages to patients depending on their individual needs. Concurrent with the development of SC trastuzumab, IV trastuzumab biosimilars comprise another treatment option that, in view of their reduced cost, might improve patient access and increase cost-effectiveness for healthcare providers and payers. In this review, we seek to raise awareness of the current options available for trastuzumab so that healthcare providers can optimally treat patients according to their individual situations and preferences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink